Bioanalysis Zone

Anti-idiotypic antibodies and CAR-T cell therapies with Michael Schwenkert

0

In this interview, Michael Schwenkert (Bio-Rad Laboratories; CA, USA) describes the challenges for development of CAR-T cell therapies that can be addressed using anti-idiotypic antibodies. He discusses how Bio-Rad generates custom antibodies for this purpose and for bioanalytical PK and immunogenicity assays.


If you enjoyed this interview, you might also like…
Share:

Leave A Comment